Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] Draft guidance Technology appraisal guidance 2 April ...

Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

For further information on how we select topics for development, please see our page about topic selection ...

While annual physical checks already take place for people with long-term conditions, we've found that BMI and waist-to-height measurements aren't consistently recorded. Our new approach addresses ...

Further information The NICE-Wide Prioritisation Board have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected for evaluation.

Further information The NICE-Wide Prioritisation Board have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected for evaluation.

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

For further information on how we select topics for development, please see our page about topic selection ...

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...

Further information The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except ...

A list of downloadable documents created during development.